Anti-PD1

DRUG5 trials

Conditions

Colorectal AdenocarcinomasEsophageal AdenocarcinomasGastric AdenocarcinomasGastrointestinal TumorsMelanoma (Skin)Melanoma Stage IIIMetastatic CancerNasopharyngeal Cancinoma (NPC)

Phase 1

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

TerminatedNCT03009058

Immodulon Therapeutics LtdMetastatic Cancer

Start: 2017-05-31End: 2017-08-30Updated: 2024-11-25

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

TerminatedNCT04171141

PfizerColorectal Adenocarcinomas, Esophageal Adenocarcinomas, Gastric Adenocarcinomas +1

Start: 2019-11-19End: 2023-11-28Updated: 2025-01-16

Phase 3

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Active, not recruitingNCT05751928

BiocadMelanoma (Skin), Melanoma Stage III

Start: 2023-04-05End: 2027-06-30Updated: 2025-07-08

Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

RecruitingNCT07705243

Sun Yat-sen UniversityNasopharyngeal Cancinoma (NPC)

Start: 2026-07-20End: 2029-07-20Target: 86Updated: 2026-07-15

Unknown Phase

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

CompletedNCT06676293

Chang Gung Memorial HospitalNasopharyngeal Carcinoma (NPC)

Start: 2023-08-01End: 2024-08-01Updated: 2024-11-07

Related Papers

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Frontiers in Oncology2024-09-041 citations

Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors

Cancer Research2020-08-15

A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.

Journal of Clinical Oncology2017-05-20